1. Characterization of Plasmodium knowlesi dihydrofolate reductase-thymidylate synthase and sensitivity to antifolates.
- Author
-
Ittarat W, Pornthanakasem W, Mungthin M, Suwandittakul N, Leelayoova S, Tarnchompoo B, Yuthavong Y, Kongkasuriyachai D, and Leartsakulpanich U
- Subjects
- Base Sequence, Multienzyme Complexes genetics, Multienzyme Complexes metabolism, Plasmodium knowlesi genetics, Proguanil pharmacology, Protozoan Proteins genetics, Protozoan Proteins metabolism, Pyrimethamine pharmacology, Sequence Alignment, Tetrahydrofolate Dehydrogenase genetics, Tetrahydrofolate Dehydrogenase metabolism, Thymidylate Synthase genetics, Thymidylate Synthase metabolism, Triazines pharmacology, Antimalarials pharmacology, Folic Acid Antagonists pharmacology, Multienzyme Complexes antagonists & inhibitors, Plasmodium knowlesi drug effects, Protozoan Proteins antagonists & inhibitors, Thymidylate Synthase antagonists & inhibitors
- Abstract
Malaria caused by an infection of Plasmodium knowlesi can result in high parasitemia and deaths. Therefore, effective and prompt treatment is necessary to reduce morbidity and mortality. The study aims to characterize P. knowlesi dihydrofolate reductase-thymidylate synthase enzyme (PkDHFR-TS) and its sensitivity to antifolates. The putative Pkdhfr gene was PCR amplified from field isolates collected from the Southern Thailand. Molecular analysis showed 11 polymorphisms in the dhfr domain of the bifunctional dhfr-ts gene. Of these, 1 polymorphism was a non-synonymous substitution (R34L) that had previously been reported but not associated with antifolate resistance. The recombinant PkDHFR-TS enzyme was found to be sensitive to standard antifolates-pyrimethamine and cycloguanil-as well as P218, a registered candidate drug currently first in human clinical trial. Results suggest that antifolates class of compounds should be effective against P. knowlesi infection., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF